Enrollment for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of the SKYWAY basket trial are complete

Company reiterates expected Q3 2026 readout for rheumatoid arthritis (RA) and Q4 2026 readouts for PsA and axSpA

Across SKYWAY and SKYLINE trials, planned ‘6 in '26' Phase 2 readouts enabled and on track

Preclinical data supporting SPY072 in rheumatic diseases presented at 2026 European Congress of Rheumatology (EULAR)

WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced the completion of enrollment for all sub-studies in the SKYWAY basket trial of SPY072 (anti-TL1A) in rheumatic diseases.